Ciara Curtin
Senior Editor at GenomeWeb
I am a science writer and editor. I also like food, running, and yoga. All views expressed here are my own.
Articles
-
3 weeks ago |
precisionmedicineonline.com | Ciara Curtin
NEW ORLEANS – Certain markers of gene-splicing correction may predict functional improvements among myotonic dystrophy type 1 (DM1) patients treated with Dyne Therapeutics' investigational antisense oligonucleotide (ASO), according to early results presented at the American Society of Gene & Cell Therapy's annual meeting. Dyne is evaluating the ASO, dubbed DYNE-101, in about 104 DM1 patients in the Phase I/II ACHIEVE clinical trial.
-
3 weeks ago |
precisionmedicineonline.com | Ciara Curtin
NEW ORLEANS – Older Duchenne muscular dystrophy patients treated with Sarepta Therapeutics' Elevidys (delandistrogene moxeparvovec) showed evidence of slowing disease progression or disease stabilization, according to data from the Phase III EMBARK trial presented at the American Society of Gene and Cell Therapy's annual meeting.
-
3 weeks ago |
precisionmedicineonline.com | Jessica Cohen |Ciara Curtin
NEW ORLEANS – At the American Society of Gene & Cell Therapy's annual meeting held here this week, researchers and drugmakers presented data on their products for treating various rare and genetic diseases. Below are brief reports on presentations from Wednesday and Thursday.
-
3 weeks ago |
precisionmedicineonline.com | Ciara Curtin
NEW ORLEANS – Investigators developed a personalized base-editing therapy for an infant with a urea cycle disorder and treated him with the bespoke therapy within a few months of his birth, according to data presented Thursday by the University of Pennsylvania's Kiran Musunuru at the American Society of Gene & Cell Therapy meeting.
-
3 weeks ago |
precisionmedicineonline.com | Ciara Curtin
NEW YORK – Cell and gene therapies have the potential to be one-time treatments for a range of diseases from lymphoma and leukemia to sickle cell and HIV. Even though many of these diseases disproportionately affect people living in low- and middle-income countries, patients have limited access to these advanced treatments in part due to their high cost.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 136
- Tweets
- 557
- DMs Open
- No
RT @ATLUTD: THAT'S HOW WE DO IT IN ATLANTA. #UniteThe404 https://t.co/6JrzS5Z4UZ
RT @JessicaKimCohen: A spate of consortiums, non-profits & research efforts are cropping up to build momentum for antisense oligonucleotide…
RT @Ch_Hops: Lots of #precisiononcology #cancertreatment news coming out of Madrid this weekend. Here's a little thread of my indefatigable…